Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5% – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) was down 6.5% during trading on Friday . The stock traded as low as $31.39 and last traded at $31.3950. Approximately 545,932 shares changed hands during trading, a decline of 57% from the average daily volume of 1,262,229 shares. The stock had previously closed at $33.58.

Wall Street Analyst Weigh In

Several research analysts recently commented on CAPR shares. B. Riley Financial increased their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, March 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Finally, Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the company an “overweight” rating in a research report on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.09.

Capricor Therapeutics Price Performance

The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -13.68 and a beta of 0.48. The stock has a 50-day moving average price of $31.11 and a 200-day moving average price of $22.54.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). Equities analysts forecast that Capricor Therapeutics, Inc. will post 0.01 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Karimah Es Sabar sold 7,529 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total value of $240,928.00. Following the completion of the sale, the director directly owned 7,529 shares of the company’s stock, valued at $240,928. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total value of $753,250.00. Following the sale, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at approximately $247,758.99. The trade was a 75.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 147,529 shares of company stock valued at $4,509,940. Insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. ACT Capital Management LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth approximately $43,000. GoalVest Advisory LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth approximately $59,000. Allworth Financial LP lifted its holdings in Capricor Therapeutics by 5,021.5% during the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 3,264 shares during the last quarter. Farther Finance Advisors LLC acquired a new stake in Capricor Therapeutics during the 3rd quarter worth approximately $28,000. Finally, State of Wyoming lifted its holdings in Capricor Therapeutics by 76.0% during the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 1,913 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.